Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | MTOR | P42345 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.77 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.77 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20967857 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL14946394 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL20459954 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL14929347 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL453447 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL453448 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6397305 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL20628772 | 0.94 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL6331089 | 0.90 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL15668496 | 0.89 | LMNA (0.60) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2971010-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Moderna Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2793906-A2 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | Moderna Therapeutics, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014152211-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2013106496-A1 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER | modeRNA Therapeutics (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013096709-A2 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | WO | disclosed |